Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Ensysce Biosciences, Inc. (LACQ)
|
Add to portfolio |
|
|
|
| Price: |
$12.87
| | Metrics |
| OS: |
1.28
|
M
| |
|
|
| Market cap: |
$16.5
|
M
| |
|
|
|
Net cash:
|
$3.83
|
M
| |
$2.98
|
per share
|
|
EV:
|
$12.7
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 2.5 | 3.5 | 3.9 | 0.0 | 0.6 |
| Revenue growth | -28.5% | -10.2% | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 2.5 | 3.5 | 3.9 | 0.0 | 0.6 |
| Gross margin | 100.0% | 100.0% | 100.0% | | 100.0% |
| Selling, general and administrative | | 18.7 | 1.2 | 3.3 | 1.6 |
| Research and development | 19.8 | 4.7 | 4.4 | | |
| General and administrative | 6.9 | | | | |
| EBIT | -24.2 | -19.9 | -1.6 | -3.3 | -1.0 |
| EBIT margin | -959.9% | -562.7% | -41.0% | | -159.9% |
| Pre-tax income | -24.2 | -29.1 | -0.2 | -0.5 | 2.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.6 | 0.6 |
| Tax rate | 0.0% | 0.0% | 0.0% | | 20.7% |
| Net income | -25.1 | -29.9 | 0.1 | -1.1 | 2.1 |
| Net margin | -994.1% | -846.4% | 1.4% | | 353.7% |
| |
| Diluted EPS | ($139.42) | ($1.48) | $0.00 | ($0.16) | $0.35 |
| Shares outstanding (diluted) | 0.2 | 20.2 | 16.5 | 6.6 | 6.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|